RxDoctor Payments Data

Snigdha Singh, MD

Ophthalmology · Taylor, MINPI 1912901398

Payments from drug & device makers

$1,425in general payments, 2019–2025

Across 49 payments — averaging $29.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$267
  • Alcon$188
  • AbbVie$143
  • Biotissue Holdings Inc.$133
  • Novartis$122
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$100
  • plus $473 from 11 others

What the payments were for

  • Food & beverage$1,425100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,425 in reported general payments places this provider in the 50th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$381,657
Medicare patients
683
Services billed
3,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine23$39,254
Cyclosporine49$28,359
XiidraLifitegrast16$21,564
Latanoprost748$13,673
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol65$11,080
Brimonidine Tartrate66$10,082
LumiganBimatoprost23$9,542
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat229$4,906
Bromfenac Sodium16$4,099
ProlensaBromfenac Sodium12$4,075
CombiganBrimonidine Tartrate/Timolol15$3,300
Prednisolone Acetate67$3,189
Timolol Maleate98$3,090
Ketorolac Tromethamine121$2,955
Pilocarpine Hcl35$2,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$143$52,09661 claims
Bausch & Lomb Americas Inc.Xiidra$267$21,56416 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$100$4,07512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Taylor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →